QMS perspective for Drug device combination

FDA combination product definition says that, combination of product means combination of drug with any device, also component of combination product is regulated by different chapters of CFR, to avoid confusion for manufacturer FDA released 21CFR part4 which clarifies the idea about the components needs to be included. 对于药物设备，我们可以这么说，这些是用于递送毒品的工具。由于组合产品的快速发展，技术进步的许多机会已经出现。The need of this combination product is to make treatment safer, more effective for patients. In simple words these products are comprised of two or more FDA regulated components, one more thing to understand is that product consist from same class are not considered to be combination product. During the development of combination product, product has their own regulatory requirement. QMS is necessary for the companies to achieve their goals.

Pharma行业的观点代表了MDR 2017/745的QMS要求的水平，可适用于制药行业设计，制造，开发和销售药物装置组合产品。MDR中有一定的质量要求，

• DDC应该被注册为药品
• Need to check proper understanding between PQS (Pharmaceutical Quality System) and medical Device QMS aspects.
• . The understanding and implementation of ISO13485makes QMS easy for pharmaceutical companies to design, manufacture, develop, and distribute DDCs if we understand the MDR requirement. ISO 13485 implementation is necessary to build trust among the customers as they believe the ISO registered companies have good Quality management system.

药品质量体系（PQS）和其他相关质量体系，如US-FDA 21 CFR第4部分澄清并轻松实施QMS的MDR要求。In the US, companies must comply with FDA’s Quality System Regulation (QSR), which can be found in 21 CFR Part 820. However, the FDA enforces that compliance through formal inspections, so it’s essential that your QMS is prepared to withstand scrutiny at all times. In Europe, ISO 13485 is the standard that manufacturers follow when implementing their QMS.

QMS perspective for drug device combination and challenges:

Regulations play crucial role for drug device combination as drugs are regulated by act 21CFR210/211 whereas medical devices are regulated by the act 21CFR 820, Human cells, tissues/Ps by 21 CFR1271 etc. For the commercialization of product, it is necessary for the organization to harmonize their product development with Quality management system. There is no clear explanation neither from MDR2017/745 nor from medical product directives for human use which can give a clear idea to reader about which requirement of MDR would or would not apply to device when combined with medical product.

• 监管变革：由于法规的变化和某些规范的更新，制造商难以理解它们并尽快实施它们。2013年1月在2013年1月之后，许多草案已经推出，包括EUMDR
• In the field of medical devices and combination product many different definitions exist, these can be confusing for the customers. To market the product, it is very important to understand the terms and definitions so that the development team can work smoothly.
• 不同国家有不同的监管和批准过程，因此有必要了解该位置的标准，其中包括启动的组合产品.21CFR第4部分澄清了CGMP的职责。

21CFR第4部分涵盖了Combo产品的调节本节表示，即

• 如果您是毒品公司，您必须实施某些第21CFR820

• If you are medical device company, you only have to implement certain section of 21CFR 210/211.

QMS侧重于制造商应考虑几个因素的人的安全性。对于大多数制造商棘手和混乱的问题，可能会出现这种监管要求需要应用最终组合产品，以减少制造商FDA的这种负担，简化了21CFR 4下的方法。

To summarize this, we can say that the manufacturer should actively develop and implement an effective quality system for their final product. this should start from the early stage of product development so that the regulatory requirement is met.

Aneffective Quality management system meets customer expectations Implementation of QMS brings the effective and result oriented quality services for the organizations. Medical device sector is rapidly growing, Drug device combinations products needs to monitor during regulatory approvals to ensure high safety standard.